The patient’s enrolment has been completed & the last patient received the first dose in the P-II study evaluating UV1 + pembrolizumab vs pembrolizumab alone at 10 sites across Germany. The trial was sponsored by Martin-Luther-University Halle-Wittenberg with support from Ultimovacs
The study focuses to determine the clinical performance of UV1 vaccination as an add-on to standard pembrolizumab treatment. The 1EPs is PFS rate at 6mos. after 1st administration & 2EPs incl. PFS, OS, ORR, DoR & safety with a minimum of 12mos. follow-up, results are expected in H2’24
UV1 is being evaluated in a broad clinical development program across multiple cancer indications with different biologics & disease stages in combination with different checkpoint inhibitors
Ref: Globe Newswire | Image: Ultimovacs
Related news:- Ultimovacs Reports Results of 24-month Follow-up Study of UV1 + Pembrolizumab for 1L Treatment of Metastatic Malignant Melanoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
